Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Sees Significant Increase in Short Interest

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) saw a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 7,670,000 shares, an increase of 40.5% from the October 15th total of 5,460,000 shares. Based on an average daily volume of 31,930,000 shares, the days-to-cover ratio is currently 0.2 days. Currently, 5.6% of the shares of the company are short sold.

Tonix Pharmaceuticals Stock Performance

TNXP traded down $0.01 during trading on Friday, reaching $0.13. The company’s stock had a trading volume of 10,509,191 shares, compared to its average volume of 10,158,421. The company has a market capitalization of $17.99 million, a price-to-earnings ratio of 0.00 and a beta of 2.06. The company’s fifty day moving average price is $0.15 and its 200-day moving average price is $1.44. Tonix Pharmaceuticals has a 52-week low of $0.12 and a 52-week high of $22.14. The company has a debt-to-equity ratio of 0.13, a quick ratio of 0.72 and a current ratio of 1.15.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. The firm had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 158.64% and a negative net margin of 1,197.86%. On average, equities analysts forecast that Tonix Pharmaceuticals will post -18 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. StockNews.com started coverage on Tonix Pharmaceuticals in a report on Wednesday. They set a “sell” rating on the stock. Alliance Global Partners lifted their target price on Tonix Pharmaceuticals from $6.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, July 22nd.

Hedge Funds Weigh In On Tonix Pharmaceuticals

An institutional investor recently raised its position in Tonix Pharmaceuticals stock. Acadian Asset Management LLC increased its stake in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 335,373 shares of the company’s stock after purchasing an additional 242,358 shares during the period. Acadian Asset Management LLC owned 0.40% of Tonix Pharmaceuticals worth $61,000 as of its most recent SEC filing. Institutional investors own 82.26% of the company’s stock.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.